ClinicalTrials.gg
CompletedNCT06181006Updated Jan 14, 2025Results posted

A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants

A Phase 1 interventional study of Pirtobrutinib in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-14.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Aug 2020, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to assess the safety and tolerability of pirtobrutinib and to look at the amount of the study drug, pirtobrutinib, that gets into the blood stream and how long it takes the body to get rid of it when given in healthy adult participants. For each participant, the total duration of the study will be 46 days, including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have (BMI) within the range of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive
  • Male and female participants in good health, determined by no findings from medical history, 12-lead (ECG), vital sign measurements, or clinical laboratory evaluations as assessed by the investigator
  • Female participants of non- and male participants who follow standard methods
  • Must have comply with all study procedures, including the 8-night stay at the Clinical Research Unit (CRU) and follow-up phone call

Exclusion criteria

Exclusion Criteria:

History or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor

  • Positive serologic test for surface antigen (HBsAg), hepatitis B virus immunoglobulin M (HBV IgM) core antibody, virus (HCV) antibody, or (HIV) antibody at Screening
  • Positive polymerase chain reaction (PCR) test for COVID-19 at Screening or Check-in (Day -1)
  • Known ongoing alcohol and/or drug abuse within 2 years prior to Screening
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee)
  • Have previously completed or withdrawn from any other study investigating Pirtobrutinib (LOXO-305) and have previously received the product
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort 1: 300 mg Pirtobrutinib

    Participants received a single dose of Pirtobrutinib 300 milligram (mg) administered orally on Day 1.

    Drug: Pirtobrutinib

  • Experimental
    Cohort 2: 600 mg Pirtobrutinib

    Participants received a single dose of Pirtobrutinib 600 mg administered orally on Day 1.

    Drug: Pirtobrutinib

  • Experimental
    Cohort 3: 800 mg Pirtobrutinib

    Participants received a single dose of Pirtobrutinib 800 mg administered orally on Day 1.

    Drug: Pirtobrutinib

  • Experimental
    Cohort 4: 900 mg Pirtobrutinib

    Participants received a single dose of Pirtobrutinib 900 mg administered orally on Day 1.

    Drug: Pirtobrutinib

Interventions

  • Administered orally.

    Also known as: LOXO-305, LY3527727

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)

    TEAE is defined as an adverse event (AE) which starts on or after the first administration of study drug. A serious adverse event is defined as any AE occurring at any dose that results in any of the following outcomes: death; a life-threatening adverse drug experience; inpatient hospitalization or prolongation of existing hospitalization; a persistent or significant disability/incapacity; a congenital anomaly/birth defect; an important medical event that may require medical or surgical intervention to prevent any of the above outcomes.

    Time frame: Baseline up to 46 days

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib

    PK: AUC0-24 of Pirtobrutinib.

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24 hours post-dose)

  2. PK: Area Under the Concentration Versus Time Curve From Hour Zero to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib

    PK: AUC0-t of Pirtobrutinib.

    Time frame: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)

  3. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Pirtobrutinib

    PK: AUC0-inf of Pirtobrutinib.

    Time frame: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)

  4. PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib

    PK: %AUCextrap of pirtobrutinib.

    Time frame: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)

  5. PK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib

    PK: Cmax of Pirtobrutinib.

    Time frame: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)

  6. PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib

    PK: Tmax of Pirtobrutinib.

    Time frame: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)

  7. PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Cohort 1)

    PK: λZ of Pirtobrutinib.

    Time frame: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)

  8. PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Cohort 2)

    PK: λZ of Pirtobrutinib.

    Time frame: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)

  9. PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Cohort 3)

    PK: λZ of Pirtobrutinib.

    Time frame: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)

  10. PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Cohort 4)

    PK: λZ of Pirtobrutinib.

    Time frame: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)

  11. PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib

    PK: CL/F of Pirtobrutinib.

    Time frame: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)

  12. PK: Apparent Volume of Distribution at Terminal Phase (Vz/F) of Pirtobrutinib

    PK: Vz/F of Pirtobrutinib.

    Time frame: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)

  13. PK: Apparent Plasma Terminal Elimination Half-life (t1/2) of Pirtobrutinib

    PK: t1/2 of Pirtobrutinib.

    Time frame: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)

07

Results

Posted Jan 14, 2025

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg Pirtobrutinib
Started6666
Received at least 1 dose of study drug6666
Completed6666
Not completed0000

Outcome measures

PrimaryNumber of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)

TEAE is defined as an adverse event (AE) which starts on or after the first administration of study drug. A serious adverse event is defined as any AE occurring at any dose that results in any of the following outcomes: death; a life-threatening adverse drug experience; inpatient hospitalization or prolongation of existing hospitalization; a persistent or significant disability/incapacity; a congenital anomaly/birth defect; an important medical event that may require medical or surgical intervention to prevent any of the above outcomes.

Time frame:
Baseline up to 46 days
Reported as:
Count of participants · Participants
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)
ParticipantsCohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg Pirtobrutinib
TEAEs1003
SAEs0000
SecondaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib

PK: AUC0-24 of Pirtobrutinib.

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24 hours post-dose)
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib
hour*nanogram per milliliter (h*ng/mL)Cohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg Pirtobrutinib
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib84100 ± 27.2135000 ± 81.8200000 ± 22.6225000 ± 22.3
SecondaryPK: Area Under the Concentration Versus Time Curve From Hour Zero to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib

PK: AUC0-t of Pirtobrutinib.

Time frame:
Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
PK: Area Under the Concentration Versus Time Curve From Hour Zero to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib
hour*nanogram per milliliter (h*ng/mL)Cohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg Pirtobrutinib
PK: Area Under the Concentration Versus Time Curve From Hour Zero to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib143000 ± 29.8259000 ± 101379000 ± 16.9490000 ± 26.8
SecondaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Pirtobrutinib

PK: AUC0-inf of Pirtobrutinib.

Time frame:
Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Pirtobrutinib
hour*nanogram per milliliter (h*ng/mL)Cohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg Pirtobrutinib
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Pirtobrutinib144000 ± 30.1260000 ± 100382000 ± 16.9492000 ± 26.9
SecondaryPK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib

PK: %AUCextrap of pirtobrutinib.

Time frame:
Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)
Reported as:
Geometric mean · percentage of AUCextrap
PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib
percentage of AUCextrapCohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg Pirtobrutinib
PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib0.869 ± 39.90.504 ± 61.20.474 ± 1130.458 ± 48.1
SecondaryPK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib

PK: Cmax of Pirtobrutinib.

Time frame:
Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
PK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib
nanogram per milliliter (ng/mL)Cohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg Pirtobrutinib
PK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib6600 ± 28.79050 ± 65.913700 ± 32.813000 ± 27.1
SecondaryPK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib

PK: Tmax of Pirtobrutinib.

Time frame:
Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)
Reported as:
Median · hours
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib
hoursCohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg Pirtobrutinib
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib3.25 (1.50 to 7.00)2.75 (2.00 to 4.00)3.00 (2.50 to 7.00)4.01 (2.50 to 9.00)
SecondaryPK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Cohort 1)

PK: λZ of Pirtobrutinib.

Time frame:
Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)
Reported as:
Number · 1/hour (1/h)
PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Cohort 1)
1/hour (1/h)Cohort 1: 300 mg Pirtobrutinib
Subject 10.0367
Subject 20.0423
Subject 30.0242
Subject 40.0477
Subject 50.0285
Subject 60.0469
SecondaryPK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Cohort 2)

PK: λZ of Pirtobrutinib.

Time frame:
Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)
Reported as:
Number · 1/hour (1/h)
PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Cohort 2)
1/hour (1/h)Cohort 2: 600 mg Pirtobrutinib
Subject 10.0322
Subject 20.0317
Subject 30.0381
Subject 40.0327
Subject 50.0353
Subject 60.0368
SecondaryPK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Cohort 3)

PK: λZ of Pirtobrutinib.

Time frame:
Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)
Reported as:
Number · 1/hour (1/h)
PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Cohort 3)
1/hour (1/h)Cohort 3: 800 mg Pirtobrutinib
Subject 10.0279
Subject 20.0263
Subject 30.0339
Subject 40.0339
Subject 50.0295
Subject 60.0410
SecondaryPK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Cohort 4)

PK: λZ of Pirtobrutinib.

Time frame:
Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)
Reported as:
Number · 1/hour (1/h)
PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Cohort 4)
1/hour (1/h)Cohort 4: 900 mg Pirtobrutinib
Subject 10.0291
Subject 20.0367
Subject 30.0330
Subject 40.0313
Subject 50.0320
Subject 60.0396
SecondaryPK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib

PK: CL/F of Pirtobrutinib.

Time frame:
Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)
Reported as:
Geometric mean · liter per hour (L/h)
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib
liter per hour (L/h)Cohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg Pirtobrutinib
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib2.08 ± 30.12.31 ± 1002.10 ± 16.91.83 ± 26.9
SecondaryPK: Apparent Volume of Distribution at Terminal Phase (Vz/F) of Pirtobrutinib

PK: Vz/F of Pirtobrutinib.

Time frame:
Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)
Reported as:
Geometric mean · Liter (L)
PK: Apparent Volume of Distribution at Terminal Phase (Vz/F) of Pirtobrutinib
Liter (L)Cohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg Pirtobrutinib
PK: Apparent Volume of Distribution at Terminal Phase (Vz/F) of Pirtobrutinib57.0 ± 23.567.1 ± 96.266.1 ± 26.454.7 ± 23.2
SecondaryPK: Apparent Plasma Terminal Elimination Half-life (t1/2) of Pirtobrutinib

PK: t1/2 of Pirtobrutinib.

Time frame:
Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose)
Reported as:
Geometric mean · hours
PK: Apparent Plasma Terminal Elimination Half-life (t1/2) of Pirtobrutinib
hoursCohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg Pirtobrutinib
PK: Apparent Plasma Terminal Elimination Half-life (t1/2) of Pirtobrutinib19.0 ± 28.420.2 ± 7.7121.9 ± 16.320.7 ± 11.2

Adverse events

Collected over Upto 46 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: 300 mg Pirtobrutinib0/6 (0%)0/6 (0%)1/6 (16.7%)
Cohort 2: 600 mg Pirtobrutinib0/6 (0%)0/6 (0%)0/6 (0%)
Cohort 3: 800 mg Pirtobrutinib0/6 (0%)0/6 (0%)0/6 (0%)
Cohort 4: 900 mg Pirtobrutinib0/6 (0%)0/6 (0%)3/6 (50%)
Most frequent other events
Most frequent other events
EventCohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg Pirtobrutinib
HeadacheNervous system disorders1/60/60/62/6
PetechiaeSkin and subcutaneous tissue disorders0/60/60/61/6

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Cohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg PirtobrutinibTotal
Mean41.8 ± 11.7936.2 ± 9.1533.2 ± 10.8535.3 ± 5.4736.6 ± 9.55
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg PirtobrutinibTotal
Female42028
Male246416
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg PirtobrutinibTotal
Hispanic or Latino462315
Not Hispanic or Latino20439
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg PirtobrutinibTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American21227
White453315
More than one race00101
Unknown or Not Reported00011
Region of Enrollment
Region of Enrollment(participants)Cohort 1: 300 mg PirtobrutinibCohort 2: 600 mg PirtobrutinibCohort 3: 800 mg PirtobrutinibCohort 4: 900 mg PirtobrutinibTotal
United States666624
08

Study locations

1 site
  • Covance Clinical Research Unit
    Daytona Beach, Florida 32117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Dec 2020, 3 months.

Results were first posted in Jan 2025, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2023
First posted
Dec 26, 2023
StartActual
Aug 14, 2020
Primary completionActual
Dec 1, 2020
CompletionActual
Dec 1, 2020
Results first posted
Jan 14, 2025
Last update
Jan 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06181006
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Dec 26, 2023
Start date
Aug 14, 2020
Primary completion
Dec 1, 2020
Completion
Dec 1, 2020
Results posted
Jan 14, 2025
Last update
Jan 14, 2025

Study contacts

Renee Ward, MD, PhD
study director · Loxo Oncology, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion